Reviewing Appili Therapeutics (OTCMKTS:APLIF) & Nuvo Pharmaceuticals (OTCMKTS:MRVFF)

Valuation & Earnings

This table compares Appili Therapeutics and Nuvo Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Appili Therapeutics	$630,000.00	2.04	-$2.80 million	($0.02)	-0.53
Nuvo Pharmaceuticals	$54.98 million	0.20	-$25.70 million	($0.12)	-8.16

Appili Therapeutics has higher earnings, but lower revenue than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Appili Therapeutics and Nuvo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Appili Therapeutics	N/A	N/A	-203.73%
Nuvo Pharmaceuticals	20.88%	-1,996.22%	14.25%

Volatility & Risk

Appili Therapeutics has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Summary

Appili Therapeutics beats Nuvo Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.